InspireMD (NSPR) director files insider report on 5,073 shares

Rhea-AI Filing Summary

InspireMD, Inc. director Paul Stuka reported an insider transaction involving 5,073 shares of the company's common stock on 12/09/2025 at a weighted average price of $1.81, with trades executed between $1.80 and $1.81 per share.

After this activity, he reports beneficial ownership of 391,628 shares held directly. A further 444,195 shares are held by Osiris Investment Partners, L.P., where he serves in a managing capacity; he may be deemed to beneficially own these but expressly disclaims beneficial ownership except to the extent of his pecuniary interest, and states that no transaction occurred in those indirect holdings.

Insider Trade Summary

Net Buyer: 5,073 shares ($9,182)

Net Buy 2 txns

Insider Stuka Paul

Role Director

Bought 5,073 shs ($9K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,073	$1.81	$9K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 391,628 shares (Direct); Common Stock — 444,195 shares (Indirect, See Footnote)

Footnotes (1)

1. The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.80 to $1.81. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stuka Paul

(Last) (First) (Middle)

C/O INSPIREMD, INC.

6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)

MIAMI FL 33126

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		P		5,073	A	$1.81(1)	391,628	D
Common Stock								444,195	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $1.80 to $1.81. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

2. These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.

Remarks:

Exhibit 24.1: Power of Attorney

	/s/ Michael Lawless, Attorney-in-Fact for Paul Stuka	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did InspireMD (NSPR) director Paul Stuka report?

Director Paul Stuka reported an insider transaction in 5,073 shares of InspireMD, Inc. common stock on 12/09/2025.

At what price were the InspireMD (NSPR) shares traded in this insider transaction?

The 5,073 InspireMD common shares were traded at a weighted average price of $1.81 per share, with individual trades executed between $1.80 and $1.81.

How many InspireMD (NSPR) shares does the director own directly after the transaction?

Following the reported activity, Paul Stuka reports 391,628 shares of InspireMD common stock held directly.

What indirect InspireMD (NSPR) holdings are reported through Osiris Investment Partners?

The filing lists 444,195 shares of InspireMD common stock held by Osiris Investment Partners, L.P., where Paul Stuka serves in a managing capacity.

Does the InspireMD (NSPR) director claim full beneficial ownership of the Osiris-held shares?

No. He states he may be deemed to beneficially own the Osiris-held shares but disclaims beneficial ownership except to the extent of his pecuniary interest.

Were any transactions reported in the indirectly held InspireMD (NSPR) shares?

The filing notes that no transaction was effected by the reporting person with respect to the indirectly held Osiris shares; they are included for informational purposes only.